» Articles » PMID: 33732251

SARS-CoV-2 Causes a Different Cytokine Response Compared to Other Cytokine Storm-Causing Respiratory Viruses in Severely Ill Patients

Overview
Journal Front Immunol
Date 2021 Mar 18
PMID 33732251
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Hyper-induction of pro-inflammatory cytokines, also known as a cytokine storm or cytokine release syndrome (CRS), is one of the key aspects of the currently ongoing SARS-CoV-2 pandemic. This process occurs when a large number of innate and adaptive immune cells activate and start producing pro-inflammatory cytokines, establishing an exacerbated feedback loop of inflammation. It is one of the factors contributing to the mortality observed with coronavirus 2019 (COVID-19) for a subgroup of patients. CRS is not unique to the SARS-CoV-2 infection; it was prevalent in most of the major human coronavirus and influenza A subtype outbreaks of the past two decades (H5N1, SARS-CoV, MERS-CoV, and H7N9). With a comprehensive literature search, we collected changing the cytokine levels from patients upon infection with the viral pathogens mentioned above. We analyzed published patient data to highlight the conserved and unique cytokine responses caused by these viruses. Our curation indicates that the cytokine response induced by SARS-CoV-2 is different compared to other CRS-causing respiratory viruses, as SARS-CoV-2 does not always induce specific cytokines like other coronaviruses or influenza do, such as IL-2, IL-10, IL-4, or IL-5. Comparing the collated cytokine responses caused by the analyzed viruses highlights a SARS-CoV-2-specific dysregulation of the type-I interferon (IFN) response and its downstream cytokine signatures. The map of responses gathered in this study could help specialists identify interventions that alleviate CRS in different diseases and evaluate whether they could be used in the COVID-19 cases.

Citing Articles

Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease.

Naiditch H, Betts M, Larman H, Levi M, Rosenberg A Front Immunol. 2025; 15:1376654.

PMID: 40012912 PMC: 11861071. DOI: 10.3389/fimmu.2024.1376654.


Neurobiology of COVID-19-Associated Psychosis/Schizophrenia: Implication of Epidermal Growth Factor Receptor Signaling.

Nawa H, Murakami M Neuropsychopharmacol Rep. 2025; 45(1):e12520.

PMID: 39754403 PMC: 11702486. DOI: 10.1002/npr2.12520.


Influence of Donor-Specific Characteristics on Cytokine Responses in H3N2 Influenza A Virus Infection: New Insights from an Ex Vivo Model.

Huang C, Hsieh M, Wu Y, Huang P, Lin Y, Tsao K Int J Mol Sci. 2024; 25(20).

PMID: 39456722 PMC: 11507259. DOI: 10.3390/ijms252010941.


Characterization of Neutrophil Functional Responses to SARS-CoV-2 Infection in a Translational Feline Model for COVID-19.

Gunasekara S, Tamil Selvan M, Murphy C, Shatnawi S, Cowan S, More S Int J Mol Sci. 2024; 25(18).

PMID: 39337543 PMC: 11432149. DOI: 10.3390/ijms251810054.


Advanced nanomedicines and immunotherapeutics to treat respiratory diseases especially COVID-19 induced thrombosis.

Wu J, Zheng Y, Zhang L, Gu C, Chen W, Chang M World J Clin Cases. 2024; 12(16):2704-2712.

PMID: 38899301 PMC: 11185334. DOI: 10.12998/wjcc.v12.i16.2704.


References
1.
Channappanavar R, Fehr A, Vijay R, Mack M, Zhao J, Meyerholz D . Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016; 19(2):181-93. PMC: 4752723. DOI: 10.1016/j.chom.2016.01.007. View

2.
Acharya D, Liu G, Gack M . Dysregulation of type I interferon responses in COVID-19. Nat Rev Immunol. 2020; 20(7):397-398. PMC: 7249038. DOI: 10.1038/s41577-020-0346-x. View

3.
Chen Q, Allot A, Lu Z . LitCovid: an open database of COVID-19 literature. Nucleic Acids Res. 2020; 49(D1):D1534-D1540. PMC: 7778958. DOI: 10.1093/nar/gkaa952. View

4.
Mi Z, Ma Y, Tong Y . Avian influenza virus H5N1 induces rapid interferon-beta production but shows more potent inhibition to retinoic acid-inducible gene I expression than H1N1 in vitro. Virol J. 2012; 9:145. PMC: 3464129. DOI: 10.1186/1743-422X-9-145. View

5.
Murira A, Lamarre A . Type-I Interferon Responses: From Friend to Foe in the Battle against Chronic Viral Infection. Front Immunol. 2017; 7:609. PMC: 5165262. DOI: 10.3389/fimmu.2016.00609. View